secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCEPT INC (—)
CIK:        0001044378
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001193125-23-102909
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Biocept restates Q1-Q3 2022 results due to errors in stock-based compensation and revenue recognition
--------------------------------------------------------------------------------

- Errors included incorrect inputs in Black-Scholes calculation for options granted April 2019 and acceleration of stock-based compensation in Q1 2022.
- Revenue recognition errors: failure to reflect changes in payor class and implicit price concessions in Q2 and Q3 2022 financial statements.
- Management concluded that review controls over stock-based compensation and revenue recognition did not operate effectively, causing material errors.
- Restated quarterly financial statements are expected to be filed by April 17, 2023; previously issued Q1-Q3 2022 reports should no longer be relied upon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1044378/000119312523102909/0001193125-23-102909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1044378/000119312523102909/d496456d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-102909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer